Drug Trial Radar · NCT04657822
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
Last checked: Nov 20, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
130
Planned (sponsor's estimate)
Start
Jun 10, 2021
Primary completion
Jun 10, 2031
Study completion Jun 10, 2031
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Dec 8, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 months, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center multi-national rollover study to allow continued access to crizanlizumab for patients with sickle cell disease (SCD) who are on crizanlizumab treatment in a Novartis-sponsored study (parent study) and are benefiting from the treatment as judged by the investigator.
Conditions
- Sickle Cell Disease
Interventions
CrizanlizumabDrug
Concentrate for solution for infusion for Intravenous use
Primary outcomes
What the sponsor says the trial is designed to measure.
- Not Applicable as this protocol is to provide an option for continued access to crizanlizumab for patients with Sickle Cell Disease who have completed a prior Novartis-sponsored Crizanlizumab studyTime frame: Not Applicable - Study Completion
Locations
31 sites in 11 countries. Site status is shown where the registry gives one.
University Of Alabama
Birmingham, Alabama · Recruiting
Childrens National Hospital
Washington D.C., District of Columbia · Active not recruiting
Augusta University Georgia
Augusta, Georgia · Recruiting
East Carolina University
Greenville, North Carolina · Completed
East Carolina University
Greenville, North Carolina · Completed
Childrens Hospital of Philadelphia
Philadelphia, Pennsylvania · Active not recruiting
Cook Childrens Medical Center
Fort Worth, Texas · Completed
Novartis Investigative Site
Brussels, Belgium · Completed
Novartis Investigative Site
Laken, Belgium · Active not recruiting
Novartis Investigative Site
Liège, Belgium · Active not recruiting
Novartis Investigative Site
Salvador, Estado de Bahia, Brazil · Active not recruiting
Novartis Investigative Site
Ribeirão Preto, São Paulo, Brazil · Active not recruiting
Novartis Investigative Site
São Paulo, São Paulo, Brazil · Active not recruiting
Novartis Investigative Site
Montería, Colombia · Active not recruiting
Novartis Investigative Site
Barranquilla, Atlántico, Colombia · Recruiting
Novartis Investigative Site
Valledupar, Cesar Department, Colombia · Recruiting
Novartis Investigative Site
Cali, Valle del Cauca Department, Colombia · Active not recruiting
Novartis Investigative Site
Créteil, France · Completed
Novartis Investigative Site
Paris, France · Active not recruiting
Novartis Investigative Site
Paris, France · Completed
Novartis Investigative Site
Heidelberg, Germany · Active not recruiting
Novartis Investigative Site
Padova, PD, Italy · Active not recruiting
Novartis Investigative Site
Orbassano, TO, Italy · Completed
Novartis Investigative Site
Beirut, Lebanon · Recruiting
Novartis Investigative Site
Tripoli, Lebanon · Recruiting
Novartis Investigative Site
Khoudh, Oman · Recruiting
Novartis Investigative Site
Barcelona, Spain · Completed
Novartis Investigative Site
Madrid, Spain · Active not recruiting
Novartis Investigative Site
Hatay, Antakya, Turkey (Türkiye) · Withdrawn
Novartis Investigative Site
Adana, Saricam, Turkey (Türkiye) · Active not recruiting
Novartis Investigative Site
Adana, Yuregir, Turkey (Türkiye) · Active not recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.